Apr 18 |
Astrazeneca (AZN) Could Be a Great Choice
|
Apr 16 |
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
|
Apr 14 |
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
|
Apr 12 |
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
|
Apr 12 |
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
|
Apr 11 |
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
|
Apr 11 |
AstraZeneca hit by investor backlash over chief Pascal Soriot’s £19m pay deal
|
Apr 11 |
World risks ‘tepid Twenties’ as debt levels and inflation soar, warns IMF
|
Apr 11 |
AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot
|
Apr 11 |
UPDATE 1-AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot
|